Aveo Pharmaceuticals downgraded to Hold from Buy at Jefferies


Jefferies downgraded Aveo Pharmaceuticals citing increased regulatory risk after the FDA expressed concern regarding the overall survival trend for tivozanib in its Phase 3 renal cell cancer trial. The firm lowered its price target for shares to $11 from $30.

View Comments (0)